Container closure systems are a critical control point in ensuring the quality, sterility, and long-term stability of pharmaceutical products.
Failures at the package level introduce direct risk to patient safety and regulatory compliance, particularly for sterile and parenteral applications.
Our services are designed to deliver a fully integrated approach to container qualification and integrity testing, aligned with USP <1207> for package integrity and the USP <661> series for material and system suitability. Rather than treating these as isolated activities, we develop cohesive strategies that connect material selection, package design, and integrity performance across the full product lifecycle.
Container Closure Integrity Strategy (USP <1207>)
A compliant CCIT program is not defined by a single test method—it is defined by a scientifically justified strategy. We develop integrity programs rooted in deterministic principles, emphasizing sensitivity, reproducibility, and quantitative understanding of leak mechanisms.
Our work begins with evaluating the container system, product characteristics, and failure modes to identify the most appropriate detection technologies. From there, we establish method capability through controlled defect studies, define limits of detection, and optimize parameters to ensure robustness under real manufacturing and stability conditions.
Deterministic technologies such as vacuum decay, helium leak detection, high voltage leak detection, and headspace analysis are applied where appropriate, with supporting correlation to probabilistic methods when required for regulatory or legacy alignment. The outcome is a method that is not only validated, but also defensible—anchored in measurable performance rather than qualitative outcomes.
This approach extends beyond development into process validation and commercial use, ensuring that integrity is continuously verified throughout the lifecycle of the product.
Container & Material Qualification (USP <661> Series)
Container systems must be qualified not only for integrity, but also for material suitability and compatibility with the drug product. The USP <661> framework provides the foundation for this evaluation, spanning material characterization through full system qualification.
We support the assessment of plastic materials of construction, including physicochemical characterization and alignment with intended pharmaceutical use. This extends into extractables considerations and compatibility risk, ensuring that material selection is appropriate for both product formulation and storage conditions.
At the system level, qualification activities focus on how the container, closure, and any device interfaces function together as a complete unit. This includes evaluation of performance under expected conditions of filling, sealing, storage, transport, and administration. The goal is to ensure that the packaging system consistently maintains product quality throughout its intended lifecycle.
Integrated Lifecycle Approach
The most effective programs are built with lifecycle thinking from the outset. We structure container qualification and CCIT strategies to evolve alongside the product, beginning in development and extending through commercialization.
During early development, the focus is on understanding the interaction between product, package, and process. This includes selecting appropriate materials, identifying potential failure modes, and establishing feasibility for integrity testing methods.
As the process matures, these insights are translated into qualification activities. Seal integrity is challenged under controlled conditions, process parameters are mapped to performance outcomes, and detection methods are refined to reliably identify critical defects.
Validation then formalizes both the package and the method. At this stage, testing approaches are statistically justified, limits of detection are verified, and documentation is structured to support regulatory submission.
Once commercialized, the strategy shifts toward maintaining assurance over time. Integrity testing becomes part of stability programs, change control processes are supported with data-driven assessments, and investigations are guided by a deep understanding of system behavior.
All work is executed with direct consideration of regulatory expectations. This includes alignment with USP <1207> requirements for deterministic integrity testing, as well as the USP <661> series for material and packaging system qualification.
In addition, our approach incorporates relevant FDA guidance, ASTM methodologies, and industry best practices such as PDA Technical Report 27. The result is a program that is not only scientifically rigorous, but also structured to withstand regulatory review.
Why choose Intertek for pharmaceutical container closure integrity testing?
- 30+ years of analytical expertise in method development, validation, stability testing, trace organics, elemental impurities, and QC testing
- FDA-regulated and cGMP-compliant facility with DEA Schedule I–V handling capabilities
- End-to-end container closure expertise ensuring product integrity, safety, and stability across the full lifecycle and various packaging types and configurations
- Fully integrated USP-aligned approach combining CCIT (USP <1207>) and material qualification (USP <661>) into one cohesive strategy
- Experienced data-driven integrity testing delivering sensitive, reproducible, and regulator-defensible results
- Lifecycle-focused solutions from development through commercialization, aligned with FDA, ASTM, and industry best practices
Related Solutions
Frequently Asked Questions (FAQs)
Container Closure Integrity Testing (CCIT) verifies that a packaging system can maintain a sterile barrier and prevent contamination throughout a product’s lifecycle. It is essential for pharmaceutical and biologic products to ensure safety, quality, and regulatory compliance.
USP <1207> provides guidance on container closure integrity testing, emphasizing deterministic, quantitative methods. It is important because it establishes regulatory expectations for demonstrating package integrity and helps ensure product sterility and patient safety.
Deterministic methods are highly sensitive, quantitative techniques used to detect leaks in packaging systems. Common methods include vacuum decay, helium leak detection, high voltage leak detection, and headspace analysis, all of which provide reproducible and measurable results.
USP <661> addresses the evaluation of plastic materials used in pharmaceutical packaging. It ensures materials are safe, compatible with the drug product, and suitable for their intended use through characterization and extractables assessments.
Deterministic methods produce quantitative, reproducible results with defined detection limits, while probabilistic methods rely on pass/fail outcomes. Regulatory guidance increasingly favors deterministic approaches due to their greater sensitivity and reliability.
